Portfolio Comments (1) 18 December 2011

NovaBiotics has unique patented anti-infectives

NovaBiotics is a leading clinical stage biotechnology company focused on the design and development of first-in-class anti-infective therapies for difficult to treat, poorly served infectious conditions.

NovaBiotics has looked to nature as the template for engineering a totally novel class of antimicrobial peptide therapies and believes its patented, proprietary technology has potential to meet the need for safer, more effective antimicrobials and address the various and well described shortcomings of conventional anti-infective therapies. Its rational drug design approach and unique patented peptide anti-infective technology has already been validated through successful clinical development of the company’s lead compound, Novexatin®, a topical (brush on) treatment for fungal nail infections. A robust and exciting pipeline of drug candidates are also being developed for conditions such as life threatening blood stream fungal infections (predominantly candidaemia) and cystic fibrosis.

 

Register today for free updates of new opportunities
  • Use the Aurora Network to contact growing companies
  • Offer your professional help as executive or director
  • See new investment opportunities in high growth companies
  • We will never pass your details to other lists without your permission
Be part of the economic revival Ask us anything in confidence
Invest £1k, £10k, or £100k
  • Invest in high growth, interesting and well-researched companies
  • Aim for 3x to 10x return from your investment
  • Putting some of your investment funds into high growth businesses can make sense during difficult economic times
  • Choose whether to invest at all and how much with Aurora
  • Join Aurora Private Equity and make your funds grow
Be an angel, be part of it Ask us anything in confidence